Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma

Neuro-Oncology

Volumn 13, Issue 9, 2011, Pages 1020-1029

  Bähr, Oliver ^a   Hattingen, Elke ^a   Rieger, Johannes ^a   Steinbach, Joachim P ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bevacizumab; Calcification; Glioblastoma

Indexed keywords

BEVACIZUMAB; GADOLINIUM; IRINOTECAN; LOMUSTINE; PENTETATE ZINC; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOLOGY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR CALCINOSIS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CALCINOSIS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052781116     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor099     Document Type: Article

References (45)

1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
2. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
3. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
4. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729. (Pubitemid 350086473)
5. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. Journal of neuro-oncology. 2008;88(3):339-347.
6. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714-4721. (Pubitemid 350086472)
7. Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. Journal of neuro-oncology. 2010;96(3):423-431.
8. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.
9. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66(8):1258-1260. (Pubitemid 43739717)
10. Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. Journal of Neuro-Oncology. 2010;99(1):49-56.
11. Rieger J, Bahr O, Ronellenfitsch MW, Steinbach J, Hattingen E. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia. J Clin Oncol. 2010;28(27):e477.
12. Ringelstein A, Turowski B, Gizewski ER, et al. Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle. Rofo. 2010;182(10):868-872.
13. Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology. 2010;255(2):622-628.
14. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (New York, NY. 2005;307(5706):58-62. (Pubitemid 40093472)
15. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer cell. 2007;11(1): 83-95. (Pubitemid 46075199)
16. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. Journal of Neuropathology and Experimental Neurology. 2001;60(9):863-871. (Pubitemid 32880594)
17. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S. Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology. 2004;44(6):555-560. (Pubitemid 38845101)
18. Salvati M, Formichella AI, D'Elia A, et al. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. Journal of Neuro-Oncology. 2009;94(1):129-134.
19. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. Journal of Neuropathology and Experimental Neurology. 2002;61(4):321-328. (Pubitemid 34266783)
20. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259. (Pubitemid 46424067)
21. Bradley WG, Jr. MR appearance of hemorrhage in the brain. Radiology. 1993;189(1):15-26. (Pubitemid 23292911)
22. Bonneville F, Cattin F, Marsot-Dupuch K, Dormont D, Bonneville JF, Chiras J. T1 signal hyperintensity in the sellar region: spectrum of findings. Radiographics. 2006;26(1):93-113. (Pubitemid 43235004)
23. Boyko OB, Burger PC, Shelburne JD, Ingram P. Non-heme mechanisms for T1 shortening: pathologic, CT, and MR elucidation. Ajnr. 1992;13(5):1439-1445.
24. Farahani K, Saxton RE, Yoon HC, De Salles AA, Black KL, Lufkin RB. MRI of thermally denatured blood: methemoglobin formation and relaxation effects. Magnetic resonance imaging. 1999;17(10): 1489-1494.
25. Avrahami E, Cohn DF, Feibel M, Tadmor R. MRI demonstration and CT correlation of the brain in patients with idiopathic intracerebral calcification. Journal of neurology. 1994;241(6):381-384. (Pubitemid 24172334)
26. Finkelstein Y, Zhang N, Fitsanakis VA, Avison MJ, Gore JC, Aschner M. Differential deposition of manganese in the rat brain following subchronic exposure to manganese: a T1-weighted magnetic resonance imaging study. Isr Med Assoc J. 2008;10(11):793-798.
27. Scotti G, Scialfa G, Tampieri D, Landoni L. MR imaging in Fahr disease. Journal of computer assisted tomography. 1985;9(4):790-792. (Pubitemid 15008717)
28. Hayashi Y, Tachibana O, Muramatsu N, et al. Rathke cleft cyst: MR and biomedical analysis of cyst content. Journal of computer assisted tomography. 1999;23(1):34-38. (Pubitemid 29095464)
29. Maeder PP, Holtas SL, Basibuyuk LN, Salford LG, Tapper UA, Brun A. Colloid cysts of the third ventricle: correlation of MR and CT findings with histology and chemical analysis. Ajnr. 1990;11(3): 575-581. (Pubitemid 20232840)
30. Kucharczyk J, Kucharczyk W, Berry I, et al. Histochemical characterization and functional significance of the hyperintense signal on MR images of the posterior pituitary. Ajr. 1989;152(1):153-157. (Pubitemid 19024084)
31. Premkumar A, Marincola F, Taubenberger J, Chow C, Venzon D, Schwartzentruber D. Metastatic melanoma: correlation of MRI characteristics and histopathology. J Magn Reson Imaging. 1996;6(1): 190-194. (Pubitemid 126702464)
32. Shakudo M, Inoue Y, Ohata K, Tanaka S. Neurenteric cyst with alteration of signal intensity on follow-up MR images. Ajnr. 2001;22(3):496-498. (Pubitemid 32221414)
33. Haimes AB, Zimmerman RD, Morgello S, et al. MR imaging of brain abscesses. Ajr. 1989;152(5):1073-1085. (Pubitemid 19125142)
34. Powell T, Sussman JG, Davies-Jones GA. MR imaging in acute multiple sclerosis: ringlike appearance in plaques suggesting the presence of paramagnetic free radicals. Ajnr. 1992;13(6):1544-1546.
35. Henkelman RM, Watts JF, Kucharczyk W. High signal intensity in MR images of calcified brain tissue. Radiology. 1991;179(1):199-206.
36. Bangert BA, Modic MT, Ross JS, et al. Hyperintense disks on T1-weighted MR images: correlation with calcification. Radiology. 1995;195(2):437-443.
37. Fahr T. Idiopatische Verkalkung der Hirngefaesse. Zentralbl Allg Pathol Anat. 1930;50:128-133.
38. Suzuki S, Nishio S, Takata K, Morioka T, Fukui M. Radiation-induced brain calcification: paradoxical high signal intensity in T1-weighted MR images. Acta neurochirurgica. 2000;142(7):801-804. (Pubitemid 30450060)
39. Painter MJ, Chutorian AM, Hilal SK. Cerebrovasculopathy following irradiation in childhood. Neurology. 1975;25(2):189-194.
40. Abayomi O, Chun MS, Kelly K. Cerebral calcification and learning disabilities following cranial irradiation for medulloblastoma. Journal of the National Medical Association. 1990;82(12):833-836.
41. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology. 2010;12(3):233-242.
42. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer cell. 2004;6(6):553-563. (Pubitemid 40017699)
43. Ansari MQ, Chincanchan CA, Armstrong DL. Brain calcification in hypoxicischemic lesions: anautopsy review.Pediatricneurology.1990;6(2):94-101. (Pubitemid 20268466)
44. Iwaski Y, Kinoshita M, Takamiya K. Rapid development of basal ganglia calcification caused by anoxia. Journal of neurology, neurosurgery, and psychiatry. 1988;51(3):449-450. (Pubitemid 18097589)
45. Sue CM, Crimmins DS, Soo YS, et al. Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis. Journal of neurology, neurosurgery, and psychiatry. 1998;65(2):233-240.